arrow
A

Anthony B. El-Khoueiry

norris comprehensive cancer center
H指数:58
被引数:2.2万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Safety and efficacy of ceralasertib, an ATR kinase inhibitor, combined with olaparib: dose escalation in advanced solid tumours and dose expansion in advanced breast cancer

西拉帕替尼(一种ATR激酶抑制剂)联合奥拉帕尼的安全性与有效性:在晚期实体瘤中的剂量递增研究及在晚期乳腺癌中的剂量扩展研究

2026-09-300
OAAI
Radiomic signatures to estimate survival in patients with advanced hepatocellular carcinoma treated with sorafenib: Cancer and Leukemia Group B 80802 (Alliance)

基于索拉非尼治疗的晚期肝细胞癌患者生存预测的放射组学特征:癌症与白血病小组B 80802(联盟)研究

2025-12-020
OAAI
A multicenter dose-defining/expansion phase 1b study of first-line regorafenib plus pembrolizumab in patients with advanced hepatocellular carcinoma

一项多中心剂量定义/扩展性 Ib 期研究,评估regorafenib联合pembrolizumab作为一线疗法在晚期肝细胞癌患者中的疗效。

2025-11-010
PRE
Safety and efficacy of intratumourally administered INT230-6 in adult patients with advanced solid tumours: results from an open-label phase 1/2 dose escalation study

INT230-6局部瘤内给药在晚期实体瘤成人患者中的安全性和有效性:一项开放标签I/II期剂量递增研究的结果

2025-10-290
OAAI
Characterizing Kupffer Cell Production of CD5 Antigen-Like and Its Function on Regulating Migration of Natural Killer T Cells

表征库普弗细胞产生CD5抗原样蛋白及其对自然杀伤T细胞迁移的调控功能

2025-07-080
OAAI
Isoform specific regulation of osteopontin by AKT2 in hepatocytes and livers

AKT2对肝细胞和肝脏中骨桥蛋白异构体的特异性调控

2025-05-210
PRE
TIMEPOINT, a phase 1 study combining MTL-CEBPA with pembrolizumab, supports the immunomodulatory effect of MTL-CEBPA in solid tumors

TIMEPOINT是一项将MTL-CEBPA与pembrolizumab联合使用的I期研究,证实了MTL-CEBPA在实体瘤中的免疫调节作用。

2025-04-010
OAAI
Updated efficacy and safety of botensilimab plus balstilimab in patients with refractory metastatic sarcoma from an expanded phase I study

扩展性I期研究中,botensilimab联合balstilimab在难治性转移性肉瘤患者中的更新疗效与安全性。

2024-09-011
PRE
Phase I dose escalation study of HFB200603, a best-in-class BTLA antagonist monoclonal antibody (mAb), in monotherapy and in combination with the anti-PD-1 mAb tislelizumab (TIS) in adult patients (pts) with advanced solid tumors

HFB200603的I期剂量递增研究,HFB200603是一种同类最佳BTLA拮抗剂单克隆抗体(mAb),用于单药治疗以及与抗PD-1单克隆抗体tislelizumab(TIS)联合治疗成人晚期实体瘤患者(pts)。

2024-09-010
PRE
Botensilimab plus balstilimab in relapsed/refractory microsatellite stable metastatic colorectal cancer: a phase 1 trial
2024-06-1310
OAAI
COMPANION-002 A clinical trial of investigational drug CTX-009 plus paclitaxel vs paclitaxel in second line advanced BTC
2024-06-040
OAAI
Nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma previously treated with sorafenib: 5-year results from CheckMate 040

Nivolumab联合ipilimumab治疗先前接受索拉非尼治疗的晚期肝细胞癌患者: CheckMate 040的5年结果

2024-06-015
OAAI
Clinical activity of lirafugratinib (RLY-4008), a highly selective FGFR2 inhibitor, in patients with advanced FGFR2-altered solid tumors: The ReFocus study
2023-12-010
PRE
A phase I/II multicenter, open-label, dose-escalation, safety, pharmacodynamic, and pharmacokinetic study of Q901 administered via intravenous infusion in adult patients with selected advanced solid tumors with a cohort expansion at the recommended phase II dose
2023-10-010
OA